Welcome to our dedicated page for MESA LABORATORIES /CO/ SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESA LABORATORIES /CO/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESA LABORATORIES /CO/'s regulatory disclosures and financial reporting.
Mesa Laboratories director Jennifer Sadie Alltoft reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into common stock of Mesa Laboratories Inc. Each RSU represented one share of common stock and vested on August 15, 2026. On that date, 2,784 RSUs were exercised and disposed of as derivatives, and 2,784 shares of common stock were acquired at a stated price of $0.00 per share. Following these transactions, Alltoft directly held 7,662 shares of common stock and had no remaining holdings in the reported RSU award. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
For MESA LABORATORIES INC (MLAB), director Shiraz Shabanali Ladiwala reported the vesting and settlement of 3,810 Restricted Stock Units (RSUs) on August 15, 2026. The RSUs, each representing a contingent right to one share of common stock, were exercised at $0.00 per share, converting into 3,810 shares of common stock. Following this transaction, Ladiwala directly holds 12,333 shares of MLAB common stock.
Mesa Laboratories, Inc. (MLAB) director Shannon Hall reported the vesting and settlement of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero, and Hall now directly holds 6,973 shares of common stock.
Mesa Laboratories director R. Tony Tripeny reported the vesting and settlement of 2,784 Restricted Stock Units (RSUs) into 2,784 shares of common stock on August 15, 2026. The RSUs, each representing a contingent right to one common share, vested on that date, increasing his directly held common stock to 9,082 shares. The derivative RSU position was reduced to zero as a result of this exercise and conversion.
Mesa Laboratories director John James Sullivan reported the vesting and settlement of 2,784 Restricted Stock Units, each converting into one share of common stock at $0.00 per share, on August 15, 2026. This exercise eliminated the RSU balance and increased his directly held common stock to 20,618 shares. He is also reported as having 45,110 shares of common stock held indirectly by the “Sullivan Family Trust,” for which his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories director John James Sullivan reported selling 7,093 shares of common stock of MLAB on 2026-08-13 at $112.80 per share in a private transaction to President and CEO Siddhartha Kadia. After this sale, Sullivan directly holds 17,834 shares and is also reported as having an indirect interest in 45,110 shares held by the Sullivan Family Trust, for which his spouse is trustee; he disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Mesa Laboratories (MLAB) President and CEO Siddhartha Kadia reported that the Anjou Parekh Lifetime Access Trust, for which his spouse serves as trustee, purchased 7,093 shares of Common Stock at $112.80 per share in a private transaction from Board Chair John Sullivan. The trust now holds 7,093 shares, reported as indirect ownership. Kadia disclaims beneficial ownership of the trust’s shares except to the extent of his pecuniary interest. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Mesa Laboratories Inc. director R. Tony Tripeny reported an open-market purchase of 900 shares of the company’s common stock on 2026-08-13 at a price of $113.69 per share. Following this transaction, Tripeny’s directly held stake increased to 6,298 shares of common stock.
Mesa Laboratories, Inc. reported Q1 FY2027 revenue of $60,138, up 1.0% from $59,543 a year earlier. Gross profit rose to $39,012, with gross margin improving to 64.9% from 62.0% as lower third‑party labor, supply‑chain efficiencies and favorable mix aided margins, especially in Biopharmaceutical Development and Clinical Genomics.
Operating expense fell 5.6% to $31,981, lifting operating income to $7,031 from $3,064. Net income was $2,830 versus $4,742, largely reflecting a prior‑year foreign‑currency gain that did not recur. Operating cash flow strengthened to $14,736, supporting an $8.7 million net debt reduction; cash ended at $30,695 with $77,250 outstanding on the Revolver and full covenant compliance.
Sterilization and Disinfection Control revenue declined 3.6% on shipment‑timing issues, while Biopharmaceutical Development and Calibration Solutions grew 5.0% and 7.6%, respectively; Clinical Genomics was flat with continued China softness. Mesa paid a $0.16 per‑share dividend and expects a potential partial release of its U.S. deferred tax valuation allowance within 12 months, which could lower its 35.0% effective tax rate. No material legal proceedings or control weaknesses were identified.
Mesa Laboratories, Inc. reported first fiscal quarter 2027 results for the three months ended June 30, 2026. Revenues were $60,138 thousand, up 1.0% year over year, with growth in Biopharmaceutical Development and Calibration Solutions partly offset by declines in Sterilization and Disinfection Control and essentially flat Clinical Genomics.
Operating income rose 129% to $7,031 thousand as gross profit improved and operating expenses declined. However, net income was $2,830 thousand, down 40.3%, or $0.49 per diluted share, mainly due to nonoperating expense of $2,678 thousand versus nonoperating income of $3,948 thousand in the prior year, which had included approximately $6,150 thousand of unrealized foreign currency gains.
Non-GAAP Adjusted Operating Income (AOI) increased 16.5% to $15,035 thousand, or $2.61 per diluted share, and AOI excluding unusual items (a $382 thousand legal settlement) was $15,417 thousand, up 19.5%. The company repaid $8,656 thousand of debt, bringing its Total Net Leverage Ratio to 1.85, below its stated target of 2.0. Management emphasized disciplined execution, capital allocation and plans to provide full-year guidance in November.